CN112839956A - 安全有效治疗膝和/或髋疼痛的药物组合物 - Google Patents

安全有效治疗膝和/或髋疼痛的药物组合物 Download PDF

Info

Publication number
CN112839956A
CN112839956A CN201980066402.2A CN201980066402A CN112839956A CN 112839956 A CN112839956 A CN 112839956A CN 201980066402 A CN201980066402 A CN 201980066402A CN 112839956 A CN112839956 A CN 112839956A
Authority
CN
China
Prior art keywords
pain
pharmaceutical composition
ngf
antibody
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980066402.2A
Other languages
English (en)
Chinese (zh)
Inventor
G·迦巴
P·戴金
S·迪马蒂诺
H·高
J·马罗尼
J·戴维斯
C·斯特曼-布林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN112839956A publication Critical patent/CN112839956A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201980066402.2A 2018-08-10 2019-08-09 安全有效治疗膝和/或髋疼痛的药物组合物 Pending CN112839956A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862717435P 2018-08-10 2018-08-10
US62/717,435 2018-08-10
US201862764816P 2018-08-15 2018-08-15
US62/764,816 2018-08-15
PCT/US2019/045970 WO2020033872A1 (en) 2018-08-10 2019-08-09 A pharmaceutical composition for safe and effective treatment of knee and/or hip pain

Publications (1)

Publication Number Publication Date
CN112839956A true CN112839956A (zh) 2021-05-25

Family

ID=67811008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980066402.2A Pending CN112839956A (zh) 2018-08-10 2019-08-09 安全有效治疗膝和/或髋疼痛的药物组合物

Country Status (10)

Country Link
US (2) US11472870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833687A1 (cg-RX-API-DMAC7.html)
JP (1) JP7460598B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210043624A (cg-RX-API-DMAC7.html)
CN (1) CN112839956A (cg-RX-API-DMAC7.html)
AU (1) AU2019318556B2 (cg-RX-API-DMAC7.html)
CA (1) CA3108697A1 (cg-RX-API-DMAC7.html)
IL (1) IL280550B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021001549A (cg-RX-API-DMAC7.html)
WO (1) WO2020033872A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7532290B2 (ja) * 2021-03-09 2024-08-13 エヌ・ティ・ティ・コミュニケーションズ株式会社 患者追跡調査支援システム、患者追跡調査支援方法、支援制御装置、端末装置およびプログラム
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
US20240002491A1 (en) * 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182978A1 (en) * 2002-12-24 2008-07-31 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
US20100034818A1 (en) * 2003-07-15 2010-02-11 Amgen, Inc. Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
CN101827609A (zh) * 2007-08-10 2010-09-08 里珍纳龙药品有限公司 抗人神经生长因子的高亲和力人抗体
US20110014208A1 (en) * 2007-08-10 2011-01-20 Regeneron Pharmaceuticals, Inc. Method of Treating Osteoarthritis with an Antibody to NGF
US20110256135A1 (en) * 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
US20150147318A1 (en) * 2012-06-06 2015-05-28 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US20180147280A1 (en) * 2016-11-29 2018-05-31 Regeneron Pharmaceuticals, Inc. Method of averting opioid addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182978A1 (en) * 2002-12-24 2008-07-31 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
US20100034818A1 (en) * 2003-07-15 2010-02-11 Amgen, Inc. Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
CN101827609A (zh) * 2007-08-10 2010-09-08 里珍纳龙药品有限公司 抗人神经生长因子的高亲和力人抗体
US20110014208A1 (en) * 2007-08-10 2011-01-20 Regeneron Pharmaceuticals, Inc. Method of Treating Osteoarthritis with an Antibody to NGF
US20110256135A1 (en) * 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
US20150147318A1 (en) * 2012-06-06 2015-05-28 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US20180147280A1 (en) * 2016-11-29 2018-05-31 Regeneron Pharmaceuticals, Inc. Method of averting opioid addiction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMSTERDAM: "Fasinumab(REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee", ELSEVIER SCIENCE PUBLISHERS, vol. 155, no. 7, pages 1 - 4 *
生命经纬: "fasinumab治疗骨关节炎痛II/III临床获得成功", pages 1 - 4, Retrieved from the Internet <URL:http://www.biovip.com/mednews/201605/35307.shtml> *

Also Published As

Publication number Publication date
JP2021533142A (ja) 2021-12-02
MX2021001549A (es) 2021-04-13
IL280550A (en) 2021-03-25
AU2019318556A1 (en) 2021-03-04
US11472870B2 (en) 2022-10-18
US20220041708A1 (en) 2022-02-10
JP7460598B2 (ja) 2024-04-02
US20200048337A1 (en) 2020-02-13
WO2020033872A1 (en) 2020-02-13
IL280550B1 (en) 2025-02-01
AU2019318556B2 (en) 2026-05-14
KR20210043624A (ko) 2021-04-21
CA3108697A1 (en) 2020-02-13
IL280550B2 (en) 2025-06-01
EP3833687A1 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
CN119137149A (zh) 用于通过施用il-4r拮抗剂来治疗结节性痒疹的方法
US11491222B2 (en) Method of treating lower back pain
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
US20220356261A1 (en) Treatment for sjögren&#39;s syndrome
US20250011408A1 (en) Methods and compositions for reducing centralized pain
RU2786232C2 (ru) Фармацевтическая композиция для безопасного и эффективного лечения боли колена и/или тазобедренного сустава
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
JP2024511078A (ja) 抗il-13抗体を用いてアトピー性皮膚炎を処置する方法
HK40100361A (en) Methods of treating atopic dermatitis with anti il-13 antibodies
HK40011843A (en) A pharmaceutical composition for averting opioid addiction
EA044062B1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525